Ascent Pharmaceuticals, Inc.

Ascent Pharmaceuticals, Inc. is a private generic pharmaceutical company founded in 2012. Headquartered in Central Islip, New York, the company operates a manufacturing and laboratory facility spanning over 309,000 square feet. While Ascent is a private entity and does not disclose exact figures, its employee count is estimated to be between 100 and 500 people, with an estimated annual revenue in the range of $25 million to $50 million. Ascent has a strategic partnership with Camber Pharmaceuticals, Inc., which primarily markets and distributes Ascent's commercial products.

Ascent is an operating company focused on the development and manufacturing of generic medicines. Its product portfolio includes more than 34 drugs for the U.S. market, covering a range of therapeutic areas, including controlled substances. The company produces multiple dosage forms, such as immediate and extended-release tablets, capsules, films, solutions, and suspensions. Through its Abbreviated New Drug Application (ANDA) filings with the FDA, Ascent seeks approval to market generic versions of existing brand-name drugs.

The company's patent litigation posture is that of a defendant operating company, consistent with its business model. The provided data shows Ascent involved in one case as a defendant and none as a plaintiff. This activity is typical for a generic drug manufacturer, which often faces patent infringement lawsuits from brand-name pharmaceutical companies upon filing an ANDA to market a generic equivalent.

The tracked case, Astellas Pharma Inc. v. Ascent Pharmaceuticals, Inc., illustrates this role. Astellas sued Ascent in the U.S. District Court for the District of New Jersey after Ascent filed an ANDA for a generic version of Myrbetriq®, a drug for treating overactive bladder. In a March 2026 ruling, a federal judge found that Ascent's proposed generic product infringed on four of Astellas's patents, delaying the launch of Ascent's version of the drug.